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Abstract
Background: Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options.
Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, and their
molecular transducers were analysed in terms of mutations, amplifications and over-expression in a BTC case series.
Furthermore, we tested the efficacy of drugs targeting these molecules, as single agents or in combination with
gemcitabine, the standard therapeutic agent against BTC.
Methods: Immunohistochemistry, FISH and mutational analysis were performed on 49 BTC samples of intrahepatic
(ICCs), extrahepatic (ECCs), and gallbladder (GBCs) origin. The effect on cell proliferation of different EGFR/HER2
pathway inhibitors as single agents or in combination with gemcitabine was investigated on BTC cell lines.
Western blot analyses were performed to investigate molecular mechanisms of targeted drugs.
Results: EGFR is expressed in 100% of ICCs, 52.6% of ECCs, and in 38.5% of GBCs. P-MAPK and p-Akt are highly
expressed in ICCs (>58% of samples), and to a lower extent in ECCs and GBCs (<46%), indicating EGFR pathway
activation. HER2 is overexpressed in 10% of GBCs (with genomic amplification), and 26.3% of ECCs (half of which
has genomic amplification). EGFR or its signal transducers are mutated in 26.5% of cases: 4 samples bear mutations
of PI3K (8.2%), 3 cases (6.1%) in K-RAS, 4 (8.2%) in B-RAF, and 2 cases (4.1%) in PTEN, but no loss of PTEN
expression is detected. EGI-1 cell line is highly sensitive to gemcitabine, TFK1 and TGBC1-TKB cell lines are
responsive and HuH28 cell line is resistant. In EGI-1 cells, combination with gefitinib further increases the
antiproliferative effect of gemcitabine. In TFK1 and TGBC1-TKB cells, the efficacy of gemcitabine is increased with
addiction of sorafenib and everolimus. In TGBC1-TKB cells, lapatinib also has a synergic effect with gemcitabine.
HuH28 becomes responsive if treated in combination with erlotinib. Moreover, HuH28 cells are sensitive to
lapatinib as a single agent. Molecular mechanisms were confirmed by western blot analysis.
Conclusion: These data demonstrate that EGFR and HER2 pathways are suitable therapeutic targets for BTCs. The
combination of gemcitabine with drugs targeting these pathways gives encouraging results and further clinical
studies could be warranted.
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Biliary tract carcinomas (BTCs) are rare primary malig-
nancies originating from the epithelium of the biliary
tree and lead to intrahepatic (ICCs), extrahepatic
(ECCs), and gallbladder cancers (GBCs). Most patients
are diagnosed when the disease is unresectable and sur-
vival is poor, with less than 5% of patients surviving
beyond 5 years [1,2]. Chemotherapy has a limited
impact on the natural history of the disease and several
drugs or drug combinations have been tested with
response rates ranging from 0% to 40%. Phase II studies
have demonstrated that the best results were obtained
with gemcitabine (Gem) reaching a 36% of response rate
and 15.4 months of median survival [3]. More recently a
multicenter, randomized phase III trial (the UK ABC-02
trial) recruiting 410 patients with advanced BTCs
demonstrated that the median progression free survival
was greater with the association of Gem with cisplatin
than Gem alone (8 vs. 5 months) [4].
Effective therapeutic agents based on a better compre-
hension of cellular and molecular pathogenesis of BTCs
are required. Preclinical studies suggest that the Epider-
mal Growth Factor Receptor (EGFR), HER2, and their
pathways have a crucial role in tumor growth [5]. The
EGFR/HER2 signaling pathway exerts its biological
effects via multiple signaling cascades including
phospholipase C, Ca2+/calmodulin-dependent kinase
(CaMK/PKC), Ras/Raf/Mitogen/Activated Proteine
Kinases (MAPK), the phosphatidylinositol 3’-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR),
PI3K/Akt/GSK, and Janus-associated kinase (JAK)/signal
transducer and activator of transcription protein
(STATs) [6-8].
In addition, EGFR signaling regulates the synthesis
and secretion of several different angiogenic growth fac-
tors in tumor cells, including vascular endothelial
growth factor (VEGF), interleukin-8 (IL-8), and basic
fibroblast growth factor (bFGF) [9].
In cholangiocarcinoma, as well as in normal cholan-
giocytes, bile acids activate the two main signaling path-
ways (Ras/Raf/MAPK and the PI3K/Akt/mTOR) via a
TGF-a-dependent mechanism. Bile acid mitogenesis
may facilitate the progression of cholangiocarcinoma
and blocking the TGF-a/EGFR autocrine pathway
attenuates bile acid-stimulated growth of cholangiocarci-
noma cell lines [10-12]. On these bases, several lines of
evidence may point to the usefulness of EGFR targeting
as an adjuvant therapy in cholangiocarcinoma. We pre-
viously reported that 15% of biliary tree and gallbladder
carcinomas had EGFR gene mutations in the tyrosine
kinase (TK) domain and that the mutations led to acti-
vation of one or both of the EGFR signal transduction
pathways [13]. Some of these mutations are identical to
those previously reported to confer sensitivity to some
TK inhibitors like erlotinib and gefitinib in non small
cell lung cancer (NSCLC) [14]. However, these inhibi-
tors are ineffective if used in the presence of mutations
in EGFR downstream transducers, such as K-RAS,
B-RAF, PI3K or phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) [15]. In NSCLC,
increased copy number of the HER2 gene is associated
with gefitinib sensitivity in EGFR-positive patients, thus
supporting the use of HER2 FISH analysis for selection
of patients for TK inhibitor (TKI) therapies [16].
Somatic mutations in the PI3K gene have been fre-
quently identified in colon and gastric carcinoma, and
glioblastoma, but rarely in other cancers [17]. Functional
analyses have revealed that these mutations increased
kinase activity and induced transformation. In addition,
in vitro experiments have demonstrated that PI3K onco-
genic mutations promote sustained PI3K signaling, con-
ferring resistance to gefitinib-induced apoptosis [18].
The tumor suppressor gene PTEN, that counteracts the
activity of PI3K, was frequently mutated in high-grade
glioblastoma, melanoma, prostate, and endometrium
cancers [19]. These mutations caused loss of PTEN
expression, constitutive activation of Akt, and resistance
to gefitinib [20]. In vitro models demonstrated that the
re-establishment of PTEN expression restores sensitivity
to gefitinib [21]. All these data have derived from in
vitro studies or from different series of patients in which
only single aspects are studied therefore not allowing for
evaluation of these findings as a whole. Due to prior
experience with anti-EGFR treatment in lung and color-
ectal cancer patients, it has become clear that only a
minority of patients with specific molecular abnormal-
ities can benefit from these therapies. Philip and cowor-
kers reported some clinical activity of erlotinib as a
single agent in cholangiocarcinoma, showing that 17% of
patients were progression free after 24 weeks of treat-
ment [22]. However, the lack of immunohistochemical
and molecular studies did not allow the determination
of which subgroups of patients would benefit most from
these treatments. Strategies based on EGFR pathway tar-
geting showed promising results [23-28].
Based on these premises, we decided that a careful
investigation of EGFR- and HER2-related pathways in
BTCs should be preliminary for clinical studies with tar-
geted molecules, facilitating a guide to monitor para-
meters that are predictive of response. Therefore, the
objectives of the current study were to investigate EGFR
and HER2 pathway expression and activation in histolo-
gical sections from patients and to evaluate the in vitro
efficacy of selective inhibitors of these pathways as sin-
gle agents or in combination with gemcitabine in BTC
cell lines.
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Patients and tissues
The study was conducted on archival formalin-fixed tis-
sues derived from 49 Italian patients with BTCs diag-
nosed at the Institute for Cancer Research and
Treatment (IRCC) from 2002 to 2005. Tumor specimens
were obtained, along with prior informed consent,
before any systemic treatment. Approval of ethical com-
mittee was not needed for this study.
Histological type was determined according to World
Health Organization criteria and tumor stage at the
time of diagnosis was determined according to TNM
classification system [29,30].
Patient characteristics, including sex, age, tumor ori-
gin, stage and histological grading are summarised in
table 1.
Drugs
Erlotinib and gefitinib were gifts from Roche and Astra-
zeneca respectively. They are reversible selective inhibi-
tors of the tyrosine kinase domain of the epidermal
growth factor receptor (EGFR). They act competitively
at the ATP-binding site of the EGFR in order to inhibit
ligand-induced tyrosine phosphorylation, thereby block-
ing ligand-induced activation of the receptor and down-
stream pathways.
Lapatinib, sorafenib, and everolimus were purchased by
Sequoia (Sequoia Research Products Pangbourne, UK).
Lapatinib inhibits receptor signal processes by binding
to the ATP-binding pocket of the EGFR/HER2 protein
kinase domain, preventing self-phosphorylation and sub-
sequent activation of the signal mechanism.
Sorafenib is a multikinase inhibitor that blocks
tumor cell proliferation and angiogenesis by inhibiting
serine/threonine kinases (c-RAF, mutant and wild-type
B-RAF) as well as the receptor tyrosine kinases vascu-
lar endothelial growth factor receptor 2 (VEGFR2),
VEGFR3, platelet-derived growth factor receptor
(PDGFR), FLT3, Ret, and c-KIT. It has also been
reported that sorafenib induces apoptosis through
the inhibition of the translation and down-regulation
of myeloid cell leukemia-1 (Mcl-1), a Bcl-2 family
member.
Everolimus is a signal transduction inhibitor targeting
mTOR (mammalian target of rapamycin)
Table 1 Clinicalpathological parameters of BTC case
series
Sample Sex Age Origin TNM * Grade
1 M 75 GBC T3N0M0 2
2 M 72 ICC T3N1M0 3
3 F 48 ICC T3N0M0 3
4 M 46 ECC T3N1M0 3
5 M 70 ECC T3N1M0 3
6 M 74 ECC T3N1M0 3
7 M 69 ICC TxN1M1 3
8 M 47 ICC TxN1M1 2
9 F 50 ICC T1N0M0 2
10 M 67 ICC T3N0M0 2
11 M 50 ICC T2NxM0 3
12 F 54 GBC TxN1M1 2
13 M 73 ECC T3N0M0 3
14 M 64 ECC T3N0M0 2
15 M 53 ECC T3N0M0 2
16 M 63 ECC T4N0M0 2
17 F 57 ECC T3N2M0 3
18 M 74 ECC T2N1M0 3
19 M 69 ECC T2N0M0 1
20 M 68 GBC T2N0M0 2
21 M 66 ICC T3N1M0 3
22 M 64 ECC T2N0M0 3
23 F 75 GBC T3NxM0 3
24 M 72 ECC T3N1M0 2
25 F 66 ICC T4N1M0 3
26 F 70 ECC TxN1M0 1
27 F 71 GBC T2N1M0 3
28 F 78 GBC T2NxM0 3
29 F 60 ECC T3N1M0 3
30 F 51 GBC T3N1M0 2
31 F 41 ICC NA 3
32 F 69 GBC T2N1M0 3
33 F 84 GBC T2NxM0 3
34 M 83 GBC T2NxM0 3
35 M 56 GBC T2NxM0 3
36 F 61 ICC TxNxM1 3
37 F 72 ICC TxNxM0 3
38 F 69 GBC T3N0M0 3
39 M 52 ICC TxNxM0 3
40 M 67 ECC TxNxM0 2
41 M 66 ICC T3NxM0 3
42 F 53 ECC T3N1M0 2
43 M 68 ECC TxNxM0 3
44 F 73 ECC T2N0M0 2
45 F 55 GBC T4N1M0 3
46 M 53 ICC TxNxM1 3
Table 1: Clinicalpathological parameters of BTC case ser-
ies (Continued)
47 M 66 ICC T3NxM0 3
48 F 53 ICC TxNxM0 3
49 M 67 ECC T4N1M0 2
ICC: Intrahepatic cholangiocarcinoma; ECC: Extrahepatic cholangiocarcinoma;
GBC: Gallbladder carcinoma, * TNM staging (see ref. [30])
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Louis, MO, USA). Gemcitabine (GEMZAR) was from
Lilly USA, and is a nucleoside analog that interferes
with DNA replication.
Cell lines and treatments
Four human cell lines of different histotype were used:
two ECC cell lines- TFK1 and EGI-1 (WT and mutated
on K-RAS respectively) kindly provided by Scherubl
from the Institute of Physiology, Charité-Universitätsme-
dizin Berlin, Germany; one ICC cell line- HuH28
(mutated on PI3K); and one GBC cell line- TGBC1-TKB
(deleted on PTEN) obtained from Cell Bank, RIKEN
BioResource Center, Tsukuba, Japan. All cells were cul-
tured in RPMI 1640 +10% FBS and 100 U/ml of penicil-
line/streptomicine. Cells were plated in 96 multiwell
plates in a concentration of 3000 cells/well and incu-
bated with 1:5 scalar doses of drugs (from 10 μMt o
16 nM) for 72 hours. For combination experiments,
drugs were administered concomitantly. Proliferation
assays were performed by Cell Titer Glo Luminescent
Cell Viability Assay and acquired by DTX880 (Beckman
Coulter Inc). Drug interaction was assessed at a fixed
1:1 concentration ratio of gemcitabine and gefitinib/erlo-
tinib/sorafenib/lapatinib/everolimus. The median Dose
(Dm) inhibiting 50% of cell proliferation and its 95%
confidence interval, isobologram analysis and dose-effect
curves were calculated by CalcuSyn software (Biosoft,
Cambridge, UK) based on Chou - Talalay method. The
general equation for the classic isobologram is given by:
combination index CI = (D)1/(Dx)1 +( D ) 2/(Dx)2 where
(Dx)1 and (Dx)2 in the denominators are the concentra-
tions for D1 (gemcitabine) and D2 (targeted drug) alone
that give x% inhibition, whereas (D)1 and (D)2 in the
nominators are the doses of gemcitabine and targeted
drug in combination that also induce the same effect
(inhibit x%). CI<1, CI = 1 and CI > 1 indicated synergis-
tic, additive and antagonistic effects, respectively. Cell
lines showing Dm>10 μM were considered resistant to
drug treatments. All tests were performed in quadrupli-
cate and repeated in three independent experiments.
Mutational analysis
Genomic DNA was extracted with the QIAamp DNA
Mini Kit (Qiagen, Milan, Italy) following the manufac-
turer’s instructions. Tumor portion and surrounding
normal tissues were obtained by laser microdissector
(VSL-337ND-S, Spectra-Physics, Mountain View, CA).
Table 2 shows exons amplified by PCR with relative spe-
cific primers. The PCR products were purified using
QIAquick PCR purification kit (Qiagen Milan, Italy) and
sense and antisense sequences were obtained by using
forward and reverse primers respectively. Each exon was
sequenced using the BigDye Terminator Cycle sequence
following the PE Applied Biosystem strategy and
Applied Biosystems ABI PRISM3100 DNA Sequencer
(Applied Biosystem, Forster City, CA). All mutations
were confirmed by two independent PCR experiments
Table 2 Sequences of forward and reverse primers (5’-3’) used for PCR and sequencing
Gene Exon Forward primer Reverse primer
EGFR 18 TCAGAGCCTGTGTTTCTACCAA TGGTCTCACAGGACCACTGATT
EGFR 19 AAATAATCAGTGTGATTCGTGGAG GAGGCCAGTGCTGTCTCTAAGG
EGFR 20 ACTTCACAGCCCTGCCGTAAAC ATGGGACAGGCACTGATTTGT
EGFR 21 GCAGCGGGTTACATCTTCTTTC CAGCTCTGGCTCACACTACCAG
PIK3CA 9 GGGAAAAATATGACAAAGAAAGC CTGAGATCAGCCAAATTCAGTT
PIK3CA 20 CTCAATGATGCTTGGCTCTG TGGAATCCAGAGTGAGCTTTC
KRAS 1 GGTGGAGTATTTGATAGTGTATTAACC AGAATGGTCCTGCACCAGTAA
BRAF 15 TGCTTGCTCTGATAGGAAAATG AGCATCTCAGGGCCAAAAAT
PTEN 5 GCAACATTTCTAAAGTTACCTA CTGTTTTCCAATAAATTCTCA
PTEN 6 CATAGCAATTTAGTGAAATAACT GATATGGTTAAGAAAACTGTTC
PTEN 7 CAGTTAAAGGCATTTCCTGTG GGATATTTCTCCCAATGAAAG
PTEN 8 CTCAGATTGCCTTATAATAGTC AACTTGTCAAGCAAGTTCTTC
PTEN 9 GTTCATCTGCAAAATGGA GGTAATCTGACACAATGTCCTA
HER2 18 GTGAAGTCCTCCCAGCCCGC CTCCCATCAGAACTGCCGACC
HER2 19 TGGAGGACAAGTAATGATCTCCTGG AGACCAGAGCCCAGACCTG
HER2 20 GCCATGGCTGTGGTTTGTGATGG ATCCTAGCCCCTTGTGGACATAGG
HER2 21 GGACTCTTGCTGGGCATGTGG CCACTCAGAGTTCTCCCATGG
HER2 22 CCATGGGAGAACTCTGAGTGG TCCCTTCACATGCTGAGGTGG
HER2 23 AGACTCCTGAGCAGAACCTCTG AGCCAGCACAGCTCAGCCAC
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possible excluding the presence of the same mutation in
surrounding normal tissues.
Immunohistochemistry
EGFR and HER2 expression was evaluated using
PharmaDX (DakoCytomation, Carpenteria, CA) and
HercepTest (Dako) kits respectively following manufac-
turer’s instructions. EGFR intensity was scored from 1+
to 3+ and the threshold for positivity was 1+ staining
intensity in 1% of tumor cells. HER2 staining was scored
from 0 to 3+ using the scoring system outlined in the
Dako HercepTest.
The anti-human TGF-a monoclonal antibody (clone
213-4,4; Oncogene Research Products, Cambridge, MA)
was used for TGF-a expression established semiquantita-
tively from the percentage of TGF-a
+ cells and the stain-
ing intensity. Tumors were graded as negative (0 to less
than 10% positive cells), + (≥10% to < 25% positive cells),
++ (>25% to < 50% positive cells) and +++ (> 50% posi-
tive cells). The percentage of immunopositive cells was
calculated by counting at least 1,000 cancer cells in con-
tiguous fields with the greatest immunopositivity.
For EGFR downstream signaling detection, rabbit
polyclonal antibodies anti-p-MAPK/Thr 202/Thr 204
and anti-p-Akt/Ser 473 (all from Cell Signaling Technol-
ogy) were used. Positive immunostaining was scored +
when present in more than 40% of cells and attributed
to nuclear staining for p-MAPK and cytoplasmatic with
a faint membranous staining for p-Akt.
PTEN expression, detected with the primary antibody
anti-PTEN (clone 28H6, NeoMarkers, Fremont, CA
94539TS 106) was quantified by using a visual grading
system based on the intensity of staining and the per-
centage of positive nuclei calculated counting of 1000
cells in 3 different optical fields at 40× magnification.
PTEN immunostaining was scored into four groups
from 0 to 3 as TGF-a scoring.
Western blot analysis
Cells were lysed with boiling buffer (SDS 2.5%, TRIS
HCl 0.125 M pH 6.8), scraped, boiled for 5 minutes at
100°C and centrifuged at 14,000 rpm for 30 minutes; 40
μg of proteins were electrophoresed on SDS-PAGE and
transferred to 0.45-μm PVDF membranes (GE Health-
care). Nonspecific sites were blocked with 5% non-fat
dry milk (BioRad Laboratories, Munchen, Germany) and
membranes were immunoblotted with specific primary
antibodies overnight followed by 1 μg/mL horseradish
peroxidase conjugated secondary antibody. Antibodies
against Akt, phosphorylated-Erk1/2 (Thr202/Tyr204),
phosphorylated-Akt (Ser473), phosphorylated mTOR
(Ser 2448), mTOR, anti-mouse and anti-rabbit antibo-
dies linked with horseradish peroxidase were from Cell
Signalling Technology (Beverly, USA); antibodies for
Erk1/2, HER2, EGFR were from Santa Cruz Biotechnol-
ogy; anti-PTEN and b-ACTIN were from MILLIPORE
(Temecula, CA); antibody anti-vinculin was from Sigma
(Sigma-Aldrich, St. Louis, MO, USA).
HER2 Fluorescence In Situ Hybridization
Tissue sections (4-6 μm) were placed on silane-coated
slides, deparaffinised, dehydrated, enzymatically digested
with a commercial kit (Vysis, Downers Grove, IL, USA)
and denaturated at 75°C for 5 minutes. Spectrum-
Orange-labeled HER-2 and Spectrum-Green-labeled
centromere 17 references (PathVysion™, Vysis-Abbott)
were denaturated for 5’ at 75°C and were applied to
each slide. Slides were incubated for 5’ at 79°C for code-
naturation and placed in a humidified chamber at 37°C
overnight for the hybridisation step. After washing,
chromatin was counterstained with DAPI II (Vysis,
Downers Grove, IL, USA). An average of 40 nuclei were
analysed at five different target areas using H&E-stained
sections as histotopographic reference. Our criteria for
HER2 gene amplification were a HER2/centromere 17
ratio ≥2. Chromosome 17 numerical status was referred
as polysomic when multiple 17 centromeric signals were
present in >20% of the cancer cell population.
Statistical Analysis
The R statistical language adaptation of Fisher exact test
for non 2 × 2 contingency tables was performed in
order to detect any significant association between his-
totype and the categorical variables describing the pre-
sence of mutations in EGFR or in specific signal
transducers, the expression of EGFR, HER2, TGF-a,
p-MAPK, p-Akt and PTEN. Mean quantitative values
were compared using Student’s t-test. The significance
of difference between groups was assessed by a Pearson
correlation analysis. A P value of less than 0.05 was con-
sidered significant. All P values were two-tailed.
Results
Expression of EGFR/HER2 proteins and related
transducers in biliary tumors
Immunoreactivity for EGFR was detected in all normal
cholangiocyte and hepatocyte membranes. EGFR expres-
sion was present in all 17 ICCs: with an intensity of 3+
in 13/17 (76.5%), and 2+ in 3/17 (17.6%). One ICC with
neuroendocrine differentiation was scored 1+ (5.9%). In
the 19 ECCs, the expression pattern was more heteroge-
neous with 10/19 (52.6%) EGFR
+ cases: only 5/19
(26.3%) were scored 3+, 3/19 (15.8%) 2+, 2/19 (10.5%) 1
+ and 9/19 (47.4%) were negative. In GBCs 5/13 (38.5%)
expressed EGFR; 4/13 (30.8%) were scored 3+, 1/13
(7.7%) was 1+ and 8/13 (61.5%) were negatives. EGFR
+
cancers were significantly more frequent in ICCs than
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between EGFR expression and histological grading in
the different BTC subgroups. Figure 1 shows representa-
tive EGFR immunostaining.
W e r n e b u r ge ta l[ 1 0 ]d e m o n s t r a t e dt h a tE G F Rw a s
activated by bile acids in a TGF-a-dependent manner.
On this basis, we decided to investigate if a pathological
upregulation of this ligand might occur in cholangiocar-
cinoma cells. The expression of this ligand was analysed
by immunohistochemistry in 49 BTC samples from
patients.
T w e n t yn i n eo u to f4 9B T C( 5 9 . 2 % )r e s u l t e dp o s i t i v e
for TGF-a expression; in particular 14 out of 17 ICCs
(82.4%), 10 out of 19 (52.6%) ECCs and 5 out of 13
(38.5%) GBCs were TGF-a
+. Twenty seven out of 49
(55.1%) carcinomas displayed positive immunostaining
for both TGF-a and EGFR. There was a significant rela-
tionship between EGFR and TGF-a expression in BTCs
(p < 0.001).
HER2 expression was performed in 10 ICCs, 19 ECCs
and 10 GBCs, according to sample availability. Membra-
nous expression was present in cancer cells, while nor-
mal cholangiocytes and stromal cells were negative.
Seven of the 39 cases (17.9%) were HER2+; in particular
1/10 (10%) of ICC was scored 1+ and 1/10 (10%) GBC
was 3+. Positive immunostaining for HER2 was detected
in 5/19 (26.3%) ECCs. Figure 2 shows representative
HER2 expression on BTC samples by HercepTest.
Phosphorylation status of downstream transducers
MAPK (Erk1/2) and Akt was analysed by immunohisto-
chemistry in all 49 BTCs. As shown in table 3, 10/17
ICCs (58.8%) presented p-MAPK and 13/17 (76.5%)
were positive for p-Akt; co-expression of the two phos-
phorylated signaling proteins were detected in 10/17
(58.8%). On the contrary, in ECCs the p-MAPK or
p-Akt were only detected in 7/19 (36.8%) with co-expres-
sion in 4/19 (21%). In GBCs the pattern of activated pro-
teins was similar to that of ECC: 5/13 (38.5%) and 6/13
(46.1%) showed p-MAPK and p-Akt expression respec-
tively, while the co-activation was found in 3/13 (23.1%).
p-MAPK and p-Akt expression were higher in the ICCs
compared to ECCs and GBCs (p < 0.05).
Table 3 Expression of biomarkers and HER2 gene status
in BTC samples from patients.
Sample EGFR TGF-a P-MAPK P-AKT PTEN HER2 HER2
FISH *
10 0 - - 1 + 0 N D
2 3+ + - - 1+ 0 ND
3 3+ + - - 1+ 0 ND
4 3+ + - + 3+ 0 ND
5 3+ + - - ND 1+ ND
6 3+ + - - 1+ 0 ND
7 3+ + - + 2+ 0 ND
8 3+ +++ - + 3+ 0 ND
9 3+ 0 - - 1+ 0 ND
10 3+ 0 + + 2+ 0 ND
11 3+ +++ + + 3+ 1+ ND
12 0 0 - - ND ND ND
13 2+ + + + 2+ 0 ND
14 3+ + + - 2+ 3+ RATIO: 10
15 2+ + - - 1+ 2+ 1.4
POLYSOMY 17
16 1+ 0 - - 1+ 0 ND
17 0 0 - - 1+ 2+ 1.7
POLYSOMY 17
18 2+ + - + 1+ 0 ND
19 0 0 + + ND 2+ RATIO: 5.9
20 0 0 ND ND 3+ 0 ND
21 1+ ++ + + 3+ ND ND
22 0 0 - - 3+ 0 ND
23 0 0 - + 3+ 0 ND
24 1+ +++ + + 3+ 0 ND
25 3+ + + + 1+ 0 ND
26 0 0 - + 3+ 0 ND
27 0 0 + - 3+ ND ND
28 0 0 - - 3+ 0 ND
29 0 + + - 2+ 0 ND
30 0 + - + 1+ 3+ RATIO: 6.9
31 3+ 0 + + 3+ ND ND
32 0 ND + - 2+ 0 ND
33 3+ 0 + + 3+ 0 ND
34 3+ + - + 3+ 0 ND
35 3+ + + + 2+ ND ND
36 3+ + + + 3+ ND ND
37 3+ +++ + + 2+ ND ND
38 1+ ++ ND ND 2+ 0 ND
39 3+ + + + ND 0 ND
40 0 0 + + ND 0 ND
41 2+ + ND ND 2+ ND ND
42 3+ + ND ND 3+ 0 ND
43 0 0 - - 3+ 0 ND
Table 3: Expression of biomarkers and HER2 gene status
in BTC samples from patients. (Continued)
44 0 0 + - 2+ 0 ND
45 3+ + + + 1+ 0 ND
46 3+ + - + 3+ 0 ND
47 2+ ++ + + 1+ ND ND
48 2+ + + + 1+ ND ND
49 0 0 - - 3+ 0 ND
ND: not determined,* HER2 FISH analysed as described in the “methods” section
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normal cholangiocytes. Cancer cells showed a moderate
or strong immunostaining, while normal cells presented
weak immunostaining (score 2+ or 3+ vs 1+).
HER2 gene amplification
To determine if overexpression of HER2 protein is attri-
butable to gene amplification, FISH analysis was per-
formed on samples scored 2+ and 3+ by HercepTest.
Figure 1 Pattern of EGFR expression in the biliary tumors. EGFR expression as typical cell membrane immunostaining: weak (1+ score; A);
moderate (2+ score, B) and strong (3+ score, C). Magnification X400.
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HER2 gene amplification. In particular HER2/centromere
17 ratio were 10 and 6.9, respectively. One out of 3 speci-
mens overexpressing HER2 (scored 2+ by HercepTest)
showed HER2 gene amplification with a ratio of 5.9. The
remaining samples scored 2+ presented multiple 17 cen-
tromeric signals in more than 20% of tumor cells. The
results of FISH analysis were shown in table 3.
Mutational analysis
The mutational analysis of exons 18 to 21 of EGFR in
this series has been published in a previous work [13]
and these results, together with nine additional cases,
are summarised in table 4. In this study, we also per-
formed a systematic mutational analysis of HER2,
P I 3 K ,K - R A S ,B - R A Fa n dP T E Ns i g n a lt r a n s d u c e r s .
Sample number 39 showed a novel EGFR mutation
(TGG to TAG) consistent with a nonsense substitu-
tion (W817Stop), leading to the production of a trun-
cated protein lacking the intracytoplasmatic tail,
which contains the interaction sites with the signal
transducer PI3K.
No mutations in HER2 TK domain were detected;
40.5% of samples displayed a silent point mutation at
codon 902 (CAG to CAA), both in homo/hemizygous
and heterozygous status (data not shown).
The mutational analysis of the EGFR/HER2 intracellu-
lar effectors identified mutations in K-RAS, PI3K,
B-RAF and PTEN (table 4). Five hotspot mutations in
the helical and catalytic domain of PI3K were found in
4/49 specimens (8.2%): two were in codon 545 (ID 763
and ID 12458) and 1 in each of codons 546 (already
described as substituted with other non synonymous
codons, ID 766, ID 767, ID 6147, and ID 12459),
Figure 2 Pattern of ErbB2 expression by HercepTest in the
biliary tumors. Scoring from 0 to 3+ (A, B, negative; C 2+ and D 3
+). Magnification X200.
Table 4 Mutations of EGFR, HER2 and their transducers
found in samples from patients.
Sample EGFR KRAS
exon 2
PI3K
exon 9
PI3K
exon 20
BRAF
exon 15
PTEN
1W T W T W T W T W T W T
2W T W T W T W T W T W T
3W T W T W T W T W T W T
4W T W T W T W T W T W T
5W T W T W T W T W T W T
6W T W T W T W T W T W T
7W T W T W T W T W T W T
8W T W T W T W T W T W T
9W T W T W T W T W T W T
10 WT WT WT WT WT WT
11 WT WT WT WT WT WT
12 WT WT WT WT WT WT
13 WT WT WT WT WT WT
14 WT WT WT WT WT WT
15 WT WT WT WT WT WT
16 WT WT WT WT WT WT
17 WT WT WT WT WT WT
18 WT WT WT WT WT WT
19 WT WT WT WT WT WT
20 WT WT WT WT WT WT
21 K757R WT WT WT WT WT
22 WT G13D WT WT V600E WT
23 WT G13D E545K H1047R WT T202I/E235G
24 WT WT WT WT WT WT
25 WT WT WT WT V600E WT
26 C775Y WT WT WT WT WT
27 WT WT WT WT WT WT
28 WT WT WT WT WT WT
29 V843I WT Q546L WT WT F271L
30 WT WT WT WT WT WT
31 E872K WT E545A WT V600E WT
32 WT WT WT WT WT WT
33 WT WT WT WT WT WT
34 WT WT WT WT WT WT
35 WT WT WT WT WT WT
36 T790M WT WT WT WT WT
37 WT WT WT WT WT WT
38 WT WT WT WT WT WT
39 W817-
STOP
WT WT WT WT WT
40 WT WT WT WT WT WT
41 WT WT WT WT WT WT
42 WT WT WT F1059L WT WT
43 WT WT WT WT V600E WT
44 WT I24F WT WT WT WT
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Page 8 of 141047 (ID 775), and 1059. Three samples (6.1%) had
point mutations of K-RAS (2 were the previously
described G13 D substitution, ID 532, the third was a
novel mutation, I24F) and 4 (8.2%) had the V600E
mutation (ID 476) of B-RAF. Exons 5, 6, 7, and 8 of
PTEN have been sequenced and 3 mutations were
found in 2 samples. Namely, sample 23 had Thr to Ile
substitution at codon 202 of exon 6 and Glu to Gly sub-
stitution at codon 235 of the exon 7; sample 29 had Phe
to Leu substitution at codon 271 of exon 8. All PTEN
mutations involved codons previously found in other
tumors as bearing single base deletions or mutations (ID
5856, ID 5292 and ID 5821).
In 4 cases, mutations of multiple transducers were
present simultaneously: sample 22 had mutated B-RAF
and K-RAS; sample 23 had mutated K-RAS, PI3K and
PTEN; sample 29 had mutated EGFR, PI3K and PTEN;
sample 31 had mutated EGFR, PI3K and B-RAF
(table 4).
The percentage of PTEN labeled nuclei in tumor
samples with activating EGFR or PI3K mutations was
higher than in tissues with EGFR and PI3K wild type
displaying 62%+31 (score 3+) vs 39%+26 (score 2+)
respectively (p = 0.032). In particular, in the cases with
activating mutations involving EGFR and/or PI3K and
not PTEN, the mean of PTEN
+ cells was 80+19 (score
3+) (p = 0.002 vs wild type), suggesting that a compen-
satory change in the level of the phosphatase might
counteract EGFR pathway activation. In agreement, the
sample 39 harboring the EGFR stop codon mutation
and, presumably, associated with an inactive pathway,
had low PTEN expression (9% or score 0).
Correlation between clinical pathological parameters and
biomarkers in BTCs
To test the association between histotype and the ana-
lysed biomarkers, a generalization of the Fisher exact
test was applied. No association was found between
h i s t o t y p ea n dt h ep r e s e n c eo fE G F Rm u t a t i o n s ,
whereas a highly significant association (p = 0.00004)
was detected between histotype and EGFR expression
(high in ICCs and ECCs and low in GBCs). A slightly
significant association was found between cholongio-
carcinoma and p-Akt expression (p = 0.01) and TGF-a
expression (0.03). TGF-a and p-MAPK were more
expressed in high grade tumors (p = 0.03058 and p =
0.04 respectively). EGFR mutations were more frequently
observed in female gender (p = 0.04). The other para-
meters tested did not give significant associations with
histotype.
Expression of EGFR/HER2 proteins and activation of
related transducers in BTC cell lines
Expression of EGFR and HER2 proteins as well as their
molecular pathways were evaluated by western blot ana-
lysis on four BTC cell lines. As shown in figure 3, all cell
lines expressed EGFR and HER2 receptors. In particular,
EGI-1 cell line expressed high levels of EGFR and HER2
proteins and low levels of PTEN. TGBC1-TKB cell line
expressed high level of phosphorylated Akt, mTOR and
MAPK suggesting sustained activation of these pathways.
Figure 3 Western blot analysis of EGFR/HER2 expression and
phosphorylation of related signal transducers in BTC cell lines.
Table 5 Median dose and relative confidential interval
values of EGFR/HER2 pathway inhibitors on BTC cell
lines.
TFK1 EGI-1 HuH28 TGBC1-TKB
Erlotinib Dm (CI) 2.59 μM 5.72 μM >10 >10
(0.17-3.46) (1.9-7.5)
Gefitinib Dm (CI) 1.8 μM 2.48 μM >10 >10
(1.1-2.9) (1.5-4.03)
Lapatinib Dm (CI) 5.25 μM 4.02 μM 2.02 μM >10
(1.01-7.2) (1.01-5.9) (1.2-4.62)
Sorafenib Dm (CI) 6.2 μM 2.06 μM >10 5.9 μM
(3.1-12.4) (0.45-9.37) (3.8-7.9)
Everolimus Dm (CI) 0.20 μM 0.5 μM >10 0.42 μM
(0.02-1.76) (0.1-1.5) (0.33-0.54)
The Median doses (Dm) and relative confidential interval (CI) of targeted
therapies which affected 50% proliferation on the four cell lines (TFK1, EGI-1,
HuH28, and TGBC1-TKB) were calculated after 72 hrs of drug treatment.
T a b l e4 :M u t a t i o n so fE G F R ,H E R 2a n dt h e i rt r a n s d u c e r s
found in samples from patients. (Continued)
45 A864T WT WT WT WT WT
46 WT WT WT WT WT WT
47 WT WT WT WT WT WT
48 WT WT WT WT WT WT
49 WT WT WT WT WT WT
WT: wild type.
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Page 9 of 14In addition, HER2 membrane expression was evaluated
by immunocitochemistry. ICC cell line HuH28 showed
the highest HER2 membrane expression, scored 3+, ECC
cell lines EGI-1 and TFK-1 were scored 1+, while GBC
cell line TGBC1-TKB showed the lowest HER2 expres-
sion (Additional file 1, figure S1).
After 72 h of treatment, everolimus was able to inhibit
mTOR phosphorylation in all BTC cell lines, but did
not influence Akt and MAPK phosphorylation (Addi-
tional file 2, figure S2).
Sorafenib down-regulated MAPK phosphorylation in
all cell lines and did not influence mTOR and Akt phos-
phorylation (Additional file 3, figure S3).
Lapatinib slightly down-regulated Akt phosphorylation
in all BTC cell lines, but not MAPK nor mTOR (Addi-
tional file 4, figure S4).
Gefitinib down-regulated Akt phosphorylation only in
EGI-1 cell line (Additional file 5, figure S5) while erloti-
nib had no evident effects on Akt/mTOR and MAPK
phosphorylation (Additional file 6, figure S6).
Antiproliferative effect of gemcitabine and EGFR/HER2
pathway inhibitors in BTC cell lines
The antiproliferative effect of different molecular targeted
drugs blocking EGFR/HER2 receptor or pathways
revealed a broad range of response in BTC cell lines
(table 5 and figure 4). The ICC cell line HuH28 was resis-
tant to all drugs except lapatinib (Dm = 2.02 μM). Lapati-
nib also inhibited proliferation of EGI-1 (Dm = 4.02 μM)
and TFK1 (Dm = 5.25 μM), while TGBC1-TKB cell line
was resistant. EGFR TKIs had a significant effect on ECC
cell lines (gefitinib Dm = 1.8 μM in TFK1 and 2.48 μMi n
EGI-1 whilst erlotinib Dm = 2.59 μM in TFK1 and 5.72
in EGI-1), but no effect was revealed on the GBC cell line
TGBC1-TKB. The multi-kinase inhibitor sorafenib had a
high efficacy on EGI-1 (Dm = 2.06 μM) and a slight effect
on TFK1 and TGBC1-TKB (6.2 μMa n d5 . 9μM respec-
tively). A reduction of 50% of cell growth was obtained
with a relatively low median doses of m-TOR inhibitor
everolimus on TFK1 (Dm = 200 nM), on EGI-1 (Dm =
500 nM) and on TGBC1-TKB (Dm = 400 nM).
Figure 4 Dose effect curves of gemcitabine (gem) combined with EGFR/HER2 pathway targeted therapies on TFK1 (A); EGI-1 (B);
HuH28(C) and TGBC1-TKB (D). After 72 h of treatment with 1:5 scalar doses (10 μM, 2 μM, 400 nM, 80 nM, 16 nM) of gem alone or in
combination with targeted therapy at a fixed 1:1 ratio, antiproliferative effect was evaluated using viability test and Chou-Talalay equation by
CalcuSyn software as described in the Methods section.
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efficient on EGI-1 (Dm = 0.74 nM), moderate efficient
on TFK-1 and TGBC1-TKB (Dm = 100 nM, Dm = 280
nM respectively) and ineffective on HuH28 (Dm > 10
μM) (table 6).
The combination of targeted drugs with gemcitabine
allowed a significant reduction of median dose. Interest-
ingly, erlotinib conferred sensitivity to gemcitabine in
HuH28, resistant to the same drug as single agent and
to all other combinations. In other cell lines, the best
result was obtained with the chemotherapeutic agent
and everolimus, highly efficient on extrahepatic cell
lines, (Dm = 0.13 nM for TFK-1 and Dm = 0.57 nM for
EGI-1) and gallbladder cell line (Dm = 1 nM). For the
other combinations, responsiveness depended on cell
lines.
Discussion
The increasing of global incidence, poor prognosis and
lack of effective therapy make the management of BTCs
further emphasize the need of effective therapeutic
agents.
Gene status and protein expression of EGFR and
HER2 and their pathways may be potential biomarkers
for predicting the response to EGFR/HER2 inhibitors.
W eo b s e r v e dt h ep r e s e n c eo f1 0 0 %E G F Re x p r e s s i o n
in ICCs, 52.6% in ECCs and 38.5% in GBCs.
Mutations in the EGFR TK domain were present in
15% of cases [13]. Furthermore, the incidence of K-RAS
mutation was particularly low (6.1%). Interestingly,
changes involving codon 12, frequently mutated in other
tumor types, were not found in our series. Previous stu-
dies of K-RAS mutations in cholangiocarcinoma
revealed divergent results [31-35]. A higher occurrence
of K-RAS mutations was found in Japan and Germany
(ranging from 39% to 54%) relative to other areas such
as Thailand (from 0% to 8%) in which this tumor
occurred with high frequency. Geographical differences
in etiology or carcinogenesis of BTCs might explain this
variability.
We observed a lower incidence of B-RAF mutations
compared to that reported by Tannapfel and coworkers
(8% vs. 21% respectively) [36].
We identified PI3K mutations in 4 cases (8.2%) and
PTEN mutations in 2 cases (4.1%).
Multiple mutations of EGFR transducers were
observed in some samples. Namely, a total of 14 muta-
tions were found in 8 tumor samples and only 3 sam-
ples had a single point mutation. Consistent with
previous reports [37,38], the K-RAS and EGFR muta-
tions were not present in the same sample but, in con-
trast with another report [36], K-RAS and B-RAF
mutations were simultaneously present in one case.
However, due to the genetic heterogeneity of tumor
subclones, we cannot exclude that these mutations
would be present in two distinct cell populations.
We observed a rare frequency of PTEN mutations and
we did not find any loss of PTEN protein expression in
comparison with normal cholangiocytes; rather a stron-
ger labeling intensity and a high percentage of labeled
cells were significantly present in tumor cells compared
to normal counterparts. In particular, samples displaying
EGFR pathway activation due to transducer mutations
had the highest percentage of PTEN-labeled cells sug-
gesting that a preserved PTEN function might counter-
act the EGFR downstream pathway activation. HER2
was overexpressed only in a small group of patients, in
accordance with the results obtained by others [39] and
no mutations on the TK domain were observed.
The inhibition of EGFR/HER2 pathways in BTCs cell
lines demonstrated a broad range of response with
EGFR TKIs being more efficient on ECC cell lines. In
Table 6 Median dose and relative confidential interval values of gemcitabine alone and in combination with EGFR/
HER2 pathway inhibitors on BTC cell lines.
Dm μM (confidence interval) TFK-1 CI* EGI-1 CI* HuH28 CI* TGBC1-TKB CI*
Gemcitabine (Gem) 0.1 0.00074 > 10 0.28
(0.003-2.93) (0.0002-0.002) (0.12-0.43)
Gem + erlotinib 0.04 0.11 0.00017 0.56 > 10 0.5 0.24 0.8
(0.03-0.73) (0.00006-0.0005) (0.033-2.28)
Gem + gefitinib 0.08 0.15 0.00004 0.15 2.9 0.9 0.26 0.9
(1.1-2.9) (0.0000007-0.002) (0.15-5.3) (0.13-0.53)
Gem + lapatinib 0.07 0.36 0.03 2.01 1.5 0.13 0.6
(0.09-29.01) (0.006-0.17) (0.46-8.6) (0.06-0.27)
Gem + sorafenib 0.07 0.017 0.01 0.19 > 10 0.11 0.062
(0.000009-0.31) 0.00019-1.07) (0.05-0.23)
Gem + everolimus 0.03 0.15 0.00057 0.015 > 10 0.001 0.07
(0.004-0.43) (0.00002-0.01) (0.00007-0.022)
*CI = combination index indicates synergism when <1
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Page 11 of 14K-RAS-mutated EGI-1 cells the Dm of these drugs was
twice the Dm on K-RAS WT TFK1. Furthermore, the
presence of PI3K mutation and PTEN deletion in
the HuH28 and TGBC1-TKB cells respectively could
probably explain the resistance to these treatments
[18,20,21]. Sorafenib wasm o r ee f f e c t i v ei nK - R A S -
mutated ECC cell line in which the MAPK pathway had
a high level of activation [40]. Lapatinib was more effec-
tive in ICC cell line which had high levels of HER2
expression.
On the other hand, lapatinib was less effective on ECC
cell lines. Furthermore, GBC cell line was considered
resistant (Dm >10 μM). In fact, TFK-1 and EGI-1 cell
lines expressed low level of HER2 and GBC cell line was
negative. These results are consistent with data obtained
in breast cancer and pancreatic preclinical models
[41-44]. In addition, a phase II study on breast cancer
patients revealed that all the responders showed high
level of HER2 expression while the HER2 negative
patients were non responders [45]. In our study, the
dual inhibition of EGFR and HER2 induced by lapatinib
was less effective than the treatment with erlotinib and
gefitinib in ECC cell lines. Indeed, in a study by Wied-
mann et al., the treatment with NVP-AEE788, an EGFR/
HER2/VEGFR-2, was more effective than erlotinib and
gefitinib [46]. The direct inhibition of VEGFR-2 could
be the gain of function of this drug compared to EGFR
and HER2 inhibition. In fact, VEGFR-2 was expressed in
ECC cell lines [47]. Moreover, VEGF was overexpressed
in ICC and ECC samples from patients and regulated
metastasis development [48]. The inhibition of VEGFR
and EGFR/HER2 signaling with NVP-AEE788 or vande-
tanib (ZD6474) might be another interesting alternative
approach for the management of BTCs.
Everolimus was effective in all tested cell lines but not
in HuH28. Nonetheless, everolimus inhibited the phos-
phorylation of mTOR in all cell lines. It seems reason-
able that in HuH28 a mechanism of resistance that
overcomes mTOR inhibition may be active.
Moreover, EGFR/HER2 pathway inhibitors had syner-
gistic effect with gemcitabine treatment. The mTOR
inhibition gave rise to the strong synergistic effect in
combination with gemcitabine in extrahepatic cell lines.
Chung et al demonstrated that more than 80% of extra-
hepatic BTC displayed mTOR activation [49] that corre-
lated with poor prognosis. Interestingly, EGFR inhibitor
erlotinib was able to overcome the resistance to gemci-
tabine in the intrahepatic cell line HuH28; in fact, intra-
hepatic specimens showed the highest EGFR expression.
Surprisingly, this result was not obtained with gefitinib.
Deepening this study, by gene expression profiling of
the cell lines will contribute to the comprehension of
the different mechanisms involved in drug response.
Conclusions
In conclusion, our preclinical results demonstrated that
blocking EGFR/HER2 signaling resulted in consider-
able antiproliferative effects in in vitro models of BTC.
The employment of targeted therapies may be useful
in cholangiocarcinoma treatment and the analysis of
EGFR/HER2 pathways in patients could orientate clini-
cians to the identification of appropriate therapeutic
approach.
Additional material
Additional file 1: Figure S1: HER2 expression in BTC cell lines.A )
HuH28, scored 3+, B) EGI-1, scored 1+, C) TFK-1,scored 1+, D) TGBC1-TKB,
HER2 negative.
Additional file 2: Figure S2: Western blot analysis on mTOR, Akt,
MAPK phosphorylation after 72 h treatment with everolimus on
BTC cell lines.
Additional file 3: Figure S3: Western blot analysis on mTOR, Akt,
MAPK phosphorylation after 72 h treatment with sorafenib on BTC
cell lines.
Additional file 4: Figure S4: Western blot analysis on mTOR, Akt,
MAPK phosphorylation after 72 h treatment with lapatinib on BTC
cell lines.
Additional file 5: Figure S5: Western blot analysis on mTOR, Akt,
MAPK phosphorylation after 72 h treatment with gefitinib on BTC
cell lines.
Additional file 6: Figure S6: Western blot analysis on mTOR, Akt,
MAPK phosphorylation after 72 h treatment with erlotinib on BTC
cell lines.
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